Mk-3475 Clinical Trials

A listing of Mk-3475 medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
A Phase II Study of Combining Talimogene Laherparepvec T-VEC (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy

The purpose of this study is to test any good and bad effects of the combination of study drugs called MK-3475 (pembrolizumab) and talimogene laherparepvec (T-VEC) in melanoma patients.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

This randomized phase II trial studies how well pembrolizumab with or without stereotactic body radiation therapy works in treating patients with merkel cell cancer that has spread to other places in the body.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ? 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma(LA cSCC) (KEYNOTE-630).

The purpose of this study is to compare the recurrence-free survival (RFS), as assessed by the investigator and confirmed by biopsy, in individuals who receive pembrolizumab with individuals who receive placebo as adjuvant therapy.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, pembrolizumab (MK-3475), to look for the highest dose of pembrolizumab that can be given safely without serious side effects, to find out how pembrolizumab is absorbed and broken down, and to …

  • 0 views
  • 19 Feb, 2024
  • 1 location